Time trends in lipid lowering drug use in the Netherlands. Has the backlog of candidates for treatment been eliminated?

British Journal of Clinical Pharmacology

Volumn 53, Issue 4, 2002, Pages 379-385

  Mantel Teeuwisse, Aukje K ^a   Klungel, Olaf H ^a   Verschuren, W M Monique ^b   Porsius, Arijan J ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Drug utilization; Incidence; Lipid lowering drugs; Pharmacy records; Prevalence

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; ASSAY; CONTROLLED STUDY; DATA BASE; DRUG CHOICE; DRUG USE; DRUG UTILIZATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SEX RATIO; TIME;

AGE FACTORS; ANTILIPEMIC AGENTS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; INCIDENCE; MALE; NETHERLANDS; PREVALENCE; SEX FACTORS; TIME FACTORS;

EID: 0036224128     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01562.x     Document Type: Article

References (39)

1. Epidemiology of coronary heart disease: The Framingham study
2. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men
3. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
4. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society
5. Cholesterol consensus in The Netherlands
6. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
7. Might treatment of hypercholesterolaemia increase non-cardiac mortality?
8. Cholesterol lowering and mortality. The importance of considering initial level of risk
9. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
10. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
12. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
14. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
15. Joint British recommendations on prevention of coronary heart disease in clinical practice
16. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study
17. Time trend analysis and variations in prescribing lipid lowering drugs in general practice
18. Growth in use of statins after trials is not targeted to most appropriate patients
19. Use of statins in general practices, 1996-8: Cross sectional study
20. Improving prescribing patterns for the elderly through an online drug utilization review intervention: A system linking the physician, pharmacist, and computer
21. Use of cholesterol-lowering drugs United States 1992
22. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy
23. Validation of pharmacy records in drug exposure assessment
24. Introduction to stratified analysis
25. Completeness of prescription recording in outpatient medical records from a health maintenance organization
26. Recall accuracy for prescription medications: Self-report compared with database information
27. Recent trends in the consumption of lipid-lowering drugs in Finland
28. Use of lipid-lowering drugs from 1990 to 1994: An international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden
29. Lipid concentrations and the use of lipid lowering drugs: Evidence from a national cross sectional survey
30. Utilization of Lipid-Lowering Drugs in Spain between 1986 and 1998
31. Use of the statins in patients after acute myocardial infarction. Does evidence change practice?
32. From trial data to practical knowledge: Qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia
33. Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice
34. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
35. Undertreatment of hypercholesterolemia in a population-based study in The Netherlands
36. Use and monitoring of 'Statin' lipid-lowering drugs compared with guidelines